Skip to main content

chlorambucil

Generic: CHLORAMBUCIL·Brand: LEUKERAN

chlorambucil: 3 clinical trials tracked.

chlorambucil evidence translation

What we can confirm

3 tracked trials

No verified listed developer

What it means

AI will separate confirmed drug evidence from unknown company context.

What to watch

Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage evidence connected

Prepared research question

What is verified about chlorambucil, and what remains unknown?

Run cited research

Traceable citations · Unknowns marked

See linked entities and source evidence1 indications · 3 study sponsors
Clinical Trials (3)

A Phase 3, Open-Label, Randomized Study of BGB-16673 Compared to Investigator's Choice in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Covalent BTK Inhibitors

NCT06970743·Phase 3·ONC
Active, not recruiting

Primary endpoint: Progression-Free Survival (PFS) by IRC

InterventionalRandomizedopen153 enrolledStarted 2025-05Completion 2029-1150 sites · ChinaBeOne Medicines

A Global Multicenter Open Label Randomized Phase III Confirmatory Study of Lisaftoclax (APG-2575) in Combination With Acalabrutinib vs Immunochemotherapy in Patients With Newly Diagnosed Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma.

NCT06319456·Phase 3·AAPG
Recruiting

Primary endpoint: Progress Free Survival (PFS)

InterventionalRandomizedopen344 targetStarted 2024-04Completion 2028-0810 sites · ChinaAscentage Pharma Group Inc.

A Randomized, Multicenter, Open-Label, Phase 3 Study to Evaluate the Efficacy and Safety of Acalabrutinib Versus Chlorambucil Plus Rituximab in Subjects With Previously Untreated Chronic Lymphocytic Leukemia

NCT04075292·Phase 3·AZN
Active, not recruiting

Primary endpoint: Progression Free Survival (PFS) Assessed by BICR

InterventionalRandomizedopen155 targetStarted 2020-01Completion 2027-0146 sites · China, Philippines, Taiwan, Thailand…AstraZeneca